Dendritic cells, headhunters for anti-tumor CD8+ T cells in triple-negative breast cancer

How do we identify patients most likely to benefit from immune checkpoint blockade therapies? This month in Med, Wu and colleagues 1 Wu S.Y. Zhang S.-W. Ma D. Xiao Y. Liu Y. Chen L. Song X.-Q. Ma X.-Y. Xu Y. Chai W.J. et al. CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med. 2023; 4: 373-393https://doi.org/10.1016/j.medj.2023.04.008 Abstract Full Text Full Text PDF Scopus (1) Google Scholar identify that CCL19+ mature dendritic cells correlated with responses to anti-PD-(L)1 immunotherapy in triple-negative breast cancer patients, suggesting the use of CCL19 as a biomarker to predict patient outcomes. How do we identify patients most likely to benefit from immune checkpoint blockade therapies? This month in Med, Wu and colleagues 1 Wu S.Y. Zhang S.-W. Ma D. Xiao Y. Liu Y. Chen L. Song X.-Q. Ma X.-Y. Xu Y. Chai W.J. et al. CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med. 2023; 4: 373-393https://doi.org/10.1016/j.medj.2023.04.008 Abstract Full Text Full Text PDF Scopus (1) Google Scholar identify that CCL19+ mature dendritic cells correlated with responses to anti-PD-(L)1 immunotherapy in triple-negative breast cancer patients, suggesting the use of CCL19 as a biomarker to predict patient outcomes. CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancerWu et al.MedMay 17, 2023In BriefUnderstanding molecular portraits of dendritic cell diversity may strengthen the clinical benefit of cancer immunotherapy. Wu et al. identified a CCL19+ functional state of dendritic cells associated with immunotherapy benefit, revealed these cells to facilitate immunotherapy-responsive contexture, and demonstrated baseline CCL19 as a noninvasive predictive biomarker of anti-PD-1 backbone treatment. Full-Text PDF